Bioavailability of LY03004 and Risperdal® Consta®

Luye Pharma Group

Status and phase

Completed

Phase 1

Conditions

Schizophrenia

Schizoaffective Disorder

Treatments

Drug: LY03004

Drug: Risperdal® Consta®

Study type

Interventional

Funder types

Industry

Identifiers

NCT02091388

LY03004 MD

Details and patient eligibility

About

This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections

Full description

To assess the relative bioavailability of LY03004 compared to Risperdal® Consta® at 25 mg following multiple intramuscular injections at steady-state;
To evaluate the safety and tolerability of LY03004 following repeated intramuscular injections
To evaluate the preliminary efficacy of LY03004 following repeated intramuscular injections

Enrollment

108 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female patients aged 18 to 65 years old
Patients must have a DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder based on the Mini-International Neuropsychiatric Interview (MINI)
Patients must be clinically stable on antipsychotic medications other than risperidone or paliperidone or clozapine for at least 4 weeks prior to screening, based on clinical assessments AND a Positive and Negative Syndrome Scale (PANSS) total score less than or equal 70 at Screening Visit
Patients with a Body Mass Index in range of 18.0 to 35.0
Patients with an Informed Consent Form signed by the patient or legally authorized representative

Exclusion criteria

Patients with a mental disorders other than schizophrenia or schizoaffective disorder, according to the DSM-IV-TR
Patients who received oral risperidone or paliperidone or clozapine within 14 days prior to screening, or Risperdal® Consta® within 100 days prior to screening or paliperidone palmitate within 10 months prior to screening
Patients with neuroleptic malignant syndrome or physical fatigue associated with dehydration or malnutrition
Patients who pose a significant risk of a suicide attempt based on history, investigator's judgment or have answered "yes" to the questions 4 or 5 for current or past 30 days on the screening form of the Columbia Suicide Severity Rating Scale (C-SSRS)
Patients with a history of sensitivity to akathisia and other EPS, especially with previous use of risperidone or paliperidone
Patients with uncontrolled diabetes mellitus as indicated by a HbA1c level greater than or equal to 7%
Patients with a history of or currently having epilepsy or convulsion disorders
Patients who have had electroconvulsive therapy within the past 2 months prior to screening
Patients who used medication known to be an inducer or inhibitor for CYP 2D6 within 2 weeks prior to screening
Patients with a history of allergic reaction to risperidone or to the excipients of LY03004
Patients who have met DSM-IV-TR criteria for substance abuse or dependence with the exception of caffeine or nicotine in the past 6 months prior to screening
Patients with a history of clinically relevant cardiac arrhythmia's, cardiovascular disease, thyrotoxicosis, parkinsonism, or hemorrhagic diathesis
Patients who are currently taking medications with primarily CNS activities such as antidepressants, mood stabilizers or anticonvulsants
Patients who have participated in a clinical trial of another investigational drug within 30 days prior to screening
Female patients who are pregnant or are breastfeeding or are of childbearing potential without adequate use of contraception
Patients who have any clinically relevant hepatic, renal and cardiac dysfunction, or other medical condition or laboratory abnormality, which in the judgment of the investigator would interfere with the subject's ability to participate in the study